ScreenerHero

OKYO OKYO Pharma Limited

NAS · US · Healthcare · Biotechnology · okyopharma.com
1.410USD-3.42%Mkt Cap: 74.00M $P/E: —

OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical tria…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap74.00M USD
Enterprise Value56.03M USD
Revenue (TTM)—
Gross Profit-6.69M USD
Net Income (TTM)-8.95M USD
Revenue/Share—
Last Price1.410 USD
Fiscal Year EndMar 2026
MR QuarterMar 2026
Employees5
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.21
PEG—
EV/EBITDA-6.59
EV/Revenue—
P/S—
P/B6.21
EPS (TTM)-0.24
EPS (Forward)-0.66
52W Range
1.2658% of range3.200
52W High3.200 USD
52W Low1.265 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-72.55%
ROA-42.67%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-5.94M USD
CapEx (TTM)6.08K USD
FCF Margin—
FCF Yield-2.84%
Net Debt-20.59M USD
Net Debt/EBITDA2.42
Balance Sheet
Debt/Equity—
Current Ratio2.43
Quick Ratio2.40
Book Value/Sh0.23 USD
Cash/Share0.39 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)9.000 USD
Upside (mean)+538.3%
Target Range7.000 USD – 13.00 USD
7.000+538.3% to mean13.00
# Analysts3
Ownership
Shares Out.52.48M
Float27.94M
Insiders31.13%
Institutions20.12%
Short Interest
Short Ratio0.5d
Short % Float0.10%
Short % Out.0.08%
Shares Short42.14K
Short (prev mo.)83.45K
Technical
SMA 501.492 (-5.5%)
SMA 2001.692 (-16.7%)
Beta-0.06
S&P 52W Chg15.78%
Avg Vol (30d)70.10K
Avg Vol (10d)66.10K
Technical Indicators
RSI (14)47.6
MACD-0.0235
MACD Signal-0.0372
MACD Hist.+0.0136
BB Upper1.546 USD
BB Middle1.404 USD
BB Lower1.262 USD
BB Width20.20%
ATR (14)0.0900 USD
Vol Ratio (20d)0.44x